SCHEMBL9966967

SCHEMBL9966967

CCOC(=O)C1(Br)COC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
TSHR P16473 2/20 0.37
ALDH1A1 P00352 4/20 0.37
POLB P06746 2/20 0.37
TRPA1 O75762 1/20 0.37
LMNA P02545 4/20 0.36
HSD17B10 Q99714 1/20 0.36
ALOX15 P16050 2/20 0.34
MGAM O43451 1/20 0.34
GAA P10253 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
SOAT1 P35610 1/20 0.34
RECQL P46063 1/20 0.34
MAPT P10636 3/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ABCB11 O95342 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28286970 0.80
SCHEMBL1604412 0.77 SMN1; SMN2 (0.40) ATMALDH1A1POLBTRPA1LMNA
SCHEMBL1538030 0.77 ATM (0.43) ATMTSHRALDH1A1POLBTRPA1
SCHEMBL311023 0.77 SMN1; SMN2 (0.44) ATMALDH1A1POLBTRPA1LMNA
SCHEMBL13467944 0.75 ATM (0.42) ATMTSHRALDH1A1POLBTRPA1
SCHEMBL3472392 0.75 ATM (0.42) ATMTSHRALDH1A1POLBLMNA
SCHEMBL11547281 0.75 ATM (0.42) ATMTSHRALDH1A1POLBTRPA1
Water SCHEMBL1537978 0.75 ATM (0.42) ATMTSHRALDH1A1POLBLMNA
SCHEMBL12027548 0.72 ATM (0.40) ATMTSHRALDH1A1POLBLMNA
SCHEMBL9856940 0.71 ALDH1A1 (0.46) ATMTSHRALDH1A1POLBTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719369-A2 INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING Celloram, Inc. (US) 2026-04-08 EP disclosed
WO-2024254161-A2 INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING CELLORAM INC. (US) 2024-12-12 WO disclosed
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
US-9006450-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-14 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 US disclosed
WO-2012001107-A1 PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157425-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF P2RX5, P2RX3, ABCG2 ATM 4640/4885TSHR 4594/4885ALDH1A1 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.